GSK wants to expand its R&D facilities in England with a new $ 550 million plan from Reuters

Rejection: Fusion Media would like to remind you that the data collected on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not offered by exchanges, but are provided by market leaders; therefore, prices may not be accurate and may differ from the actual market price, i.e., prices are significant and not suitable for trading purposes. Therefore, Fusion Media does not assume any liability for any commercial losses that you may incur as a result of your use of this data.

Fusion Media or anyone related to Fusion Media will not be liable for any loss or damage based on information including data, quotes, tables and buy / sell signals on this website. Please be aware that the risks and costs associated with trading on the financial markets are one of the most risky investments possible.